
## J Julie Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2315302/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Disparities in gynecologic cancer incidence, treatment, and survival: a narrative review of outcomes among black and white women in the United States. International Journal of Gynecological Cancer, 2022, 32, 931-938.	2.5	5
2	Abstract PS19-09: Alternative splicing events from progesterone exposure differ based on BRCA1 mutation status. , 2021, , .		0
3	Reply: Exposure of human fallopian tube epithelium to elevated testosterone results in alteration of cilia gene expression and beating. Human Reproduction, 2021, 36, 1725-1725.	0.9	10
4	Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland. Breast Cancer Research, 2021, 23, 78.	5.0	7
5	Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes. Cancer Letters, 2021, 520, 255-266.	7.2	5
6	Preparing for implantation. ELife, 2021, 10, .	6.0	2
7	Scaffold-Free Endometrial Organoids Respond to Excess Androgens Associated With Polycystic Ovarian Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 769-780.	3.6	60
8	HMGA2-mediated tumorigenesis through angiogenesis in leiomyoma. Fertility and Sterility, 2020, 114, 1085-1096.	1.0	27
9	Exposure of human fallopian tube epithelium to elevated testosterone results in alteration of cilia gene expression and beating. Human Reproduction, 2020, 35, 2086-2096.	0.9	25
10	Microphysiological Modeling of the Human Endometrium. Tissue Engineering - Part A, 2020, 26, 759-768.	3.1	19
11	Generation of Multicellular Human Primary Endometrial Organoids. Journal of Visualized Experiments, 2019, , .	0.3	19
12	BRCA1 mutation influences progesterone response in human benign mammary organoids. Breast Cancer Research, 2019, 21, 124.	5.0	15
13	The AKT/BCL-2 Axis Mediates Survival of Uterine Leiomyoma in a Novel 3D Spheroid Model. Endocrinology, 2018, 159, 1453-1462.	2.8	14
14	Establishment of breast tumor spheroids: An emerging research tool. Molecular Reproduction and Development, 2018, 85, 174-174.	2.0	0
15	Mechanism of Telapristone Acetate (CDB4124) on Progesterone Receptor Action in Breast Cancer Cells. Endocrinology, 2018, 159, 3581-3595.	2.8	13
16	A small molecule inhibitor of the perinucleolar compartment, ML246, attenuates growth and spread of ovarian cancer. Gynecologic Oncology Research and Practice, 2018, 5, 7.	3.6	6
17	Application of ex-vivo spheroid model system for the analysis of senescence and senolytic phenotypes in uterine leiomyoma. Laboratory Investigation, 2018, 98, 1575-1587.	3.7	14
18	Mentorship 2.0. Endocrinology, 2018, 159, 2361-2362.	2.8	2

J JULIE KIM

#	Article	IF	CITATIONS
19	Comparative analysis of <i>AKT</i> and the related biomarkers in uterine leiomyomas with <i>MED12, HMGA2</i> , and <i>FH</i> mutations. Genes Chromosomes and Cancer, 2018, 57, 485-494.	2.8	21
20	Hormonal strategies in gynecologic cancer: Bridging biology and therapy. Gynecologic Oncology, 2018, 150, 207-210.	1.4	5
21	Oxidative stress-induced miRNAs modulate AKT signaling and promote cellular senescence in uterine leiomyoma. Journal of Molecular Medicine, 2018, 96, 1095-1106.	3.9	23
22	The allosteric AKT inhibitor, MK2206, decreases tumor growth and invasion in patient derived xenografts of endometrial cancer. Cancer Biology and Therapy, 2017, 18, 958-964.	3.4	20
23	Development of a novel human recellularized endometrium that responds to a 28-day hormone treatmentâ€. Biology of Reproduction, 2017, 96, 971-981.	2.7	51
24	Endometrial receptivity in the eutopic endometrium of women with endometriosis: it is affected, and let me show you why. Fertility and Sterility, 2017, 108, 19-27.	1.0	192
25	Paracrine Pathways in Uterine Leiomyoma Stem Cells Involve Insulinlike Growth Factor 2 and Insulin Receptor A. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1588-1595.	3.6	11
26	A microfluidic culture model of the human reproductive tract and 28-day menstrual cycle. Nature Communications, 2017, 8, 14584.	12.8	327
27	Microphysiologic systems in female reproductive biology. Experimental Biology and Medicine, 2017, 242, 1690-1700.	2.4	15
28	Synucleinâ€Î³ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer, 2017, 123, 1144-1155.	4.1	11
29	Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells. Journal of Biological Chemistry, 2017, 292, 2237-2254.	3.4	26
30	CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. Journal of Experimental Medicine, 2017, 214, 2715-2732.	8.5	67
31	Association of body mass index with ER, PR and 14-3-3 $if$ expression in tumor and stroma of type I and type II endometrial carcinoma. Oncotarget, 2017, 8, 42548-42559.	1.8	9
32	Progesterone receptor blockade in human breast cancer cells decreases cell cycle progression through G2/M by repressing G2/M genes. BMC Cancer, 2016, 16, 326.	2.6	12
33	Human fallopian tube epithelium co-culture with murine ovarian follicles reveals crosstalk in the reproductive cycle. Molecular Human Reproduction, 2016, 22, 756-767.	2.8	32
34	Dysfunctional MnSOD leads to redox dysregulation and activation of prosurvival AKT signaling in uterine leiomyomas. Science Advances, 2016, 2, e1601132.	10.3	24
35	Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma. Journal of Hematology and Oncology, 2016, 9, 92.	17.0	40
36	Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease. Journal of Ovarian Research, 2016, 9, 75.	3.0	13

J JULIE KIM

#	Article	IF	CITATIONS
37	Transcriptional Profiling of Human Endocervical Tissues Reveals Distinct Gene Expression in the Follicular and Luteal Phases of the Menstrual Cycle1. Biology of Reproduction, 2016, 94, 138.	2.7	10
38	Fenretinide:A Potential Treatment for Endometriosis. Reproductive Sciences, 2016, 23, 1139-1147.	2.5	15
39	Three-dimensional modeling of the human fallopian tube fimbriae. Gynecologic Oncology, 2015, 136, 348-354.	1.4	28
40	Novel Three Dimensional Human Endocervix Cultures Respond to 28-Day Hormone Treatment. Endocrinology, 2015, 156, 1602-1609.	2.8	29
41	Efficacy of metarrestin against ovarian cancer Journal of Clinical Oncology, 2015, 33, e16573-e16573.	1.6	0
42	Influence of AKT on Progesterone Action in Endometrial Diseases. Biology of Reproduction, 2014, 91, 63-63.	2.7	35
43	Microphysiological modeling of the reproductive tract: A fertile endeavor. Experimental Biology and Medicine, 2014, 239, 1192-1202.	2.4	25
44	Establishment of Human Patient-Derived Endometrial Cancer Xenografts in NOD scid Gamma Mice for the Study of Invasion and Metastasis. PLoS ONE, 2014, 9, e116064.	2.5	25
45	Increased AKT or MEK1/2 Activity Influences Progesterone Receptor Levels and Localization in Endometriosis. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1871-E1879.	3.6	49
46	Progesterone Action in Endometrial Cancer, Endometriosis, Uterine Fibroids, and Breast Cancer. Endocrine Reviews, 2013, 34, 130-162.	20.1	378
47	Î <sup>3</sup> -synuclein expression in ovarian cancer Journal of Clinical Oncology, 2013, 31, 5574-5574.	1.6	0
48	Increased Activation of the PI3K/AKT Pathway Compromises Decidualization of Stromal Cells from Endometriosis. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E35-E43.	3.6	122
49	Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin. PLoS ONE, 2012, 7, e41593.	2.5	45
50	The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Molecular and Cellular Endocrinology, 2012, 358, 223-231.	3.2	141
51	Role of Progesterone in Endometrial Cancer. Seminars in Reproductive Medicine, 2010, 28, 081-090.	1.1	165
52	Perinucleolar compartment prevalence is a phenotypic pancancer marker of malignancy. Cancer, 2008, 113, 861-869.	4.1	43
53	Altered expression of HOXA10 in endometriosis: potential role in decidualization. Molecular Human Reproduction, 2007, 13, 323-332.	2.8	208
54	Progesterone Receptor Regulates Bcl-2 Gene Expression through Direct Binding to Its Promoter Region in Uterine Leiomyoma Cells. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4459-4466.	3.6	79

J JULIE KIM

#	Article	IF	CITATIONS
55	Transcriptional Cross Talk between the Forkhead Transcription Factor Forkhead Box O1A and the Progesterone Receptor Coordinates Cell Cycle Regulation and Differentiation in Human Endometrial Stromal Cells. Molecular Endocrinology, 2007, 21, 2334-2349.	3.7	189
56	Progesterone resistance in endometriosis: Link to failure to metabolize estradiol. Molecular and Cellular Endocrinology, 2006, 248, 94-103.	3.2	337